The Food and Drug Administration on Friday rejecteda controversial treatment for post-traumatic stress disorder that combines ecstasy with psychotherapy.
Why it matters: The decision is a major blow to psychedelic therapy advocates and investors, who pressed for the MDMA-assisted therapy to become the first psychedelic treatment approved for clinical use in the United States.
FDA asked Lykos to conduct an additional clinical trial on the therapy, per the company.
The future of Hims & Hers — a digital-first health platform that offers content, telehealth and drug treatments related to skin care, sexual performance and mental health — may be more hers than hims.
Cutting-edge medical devices will be eligible for Medicare coverage while manufacturers continue to gather data on how they perform under a new plan finalized by the Biden administration Wednesday.
Why it matters: The long-awaitedplan offers America's seniors access to new technologies that have been cleared by the Food and Drug Administration but still have outstanding questions.It also gives manufacturers a streamlined pathway to having devices covered by Medicare, which other insurers often follow.
The Centers for Disease Control on Wednesday alerted doctors to be on the lookout for a deadly new strain of mpox spreading through parts of Africa while U.S. officials committed $424 million to the Democratic Republic of the Congo, which is the epicenter of the outbreak.
Why it matters: The so-called clade I virus is more virulent and deadly than the clade II variety that caused a global outbreak in 2022.
Community health centers' staffing shortages are getting worseas the demand for their care grows.
Why it matters: The federally funded clinics play a crucial role in the American health care safety net because they're required to care for patients regardless of their insurance status or ability to pay.
For insurers like UnitedHealth Group and Cigna, the road to ever-larger profits increasingly leads through anything but health insurance.
Why it matters: A host of earnings reports in recent weeks reinforce how much pharmacy, physician networks and other non-core products are driving the bottom lines of health behemoths with big insurance units — a situation that is grabbing the attention of regulators and Congress.
